Consensus HIV-1 subtype A integrase and its raltegravir-resistant variants: Design and characterization of the enzymatic properties

Biochimie

Volumn 102, Issue 1, 2014, Pages 92-101

  Shadrina, Olga ^a   Krotova, Olga ^b,c,d   Agapkina, Julia ^a   Knyazhanskaya, Ekaterina ^a   Korolev, Sergey ^a   Starodubova, Elizaveta ^b,d   Viklund, Alecia ^d   Lukashov, Vladimir ^c,e   Magnani, Mauro ^f   Medstrand, Patrik ^g   Karpov, Vadim ^b   Gottikh, Marina ^a   Isaguliants, Maria ^c,d  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^c D I IVANOVSKY INSTITUTE OF VIROLOGY   (Russian Federation)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f UNIVERSITY OF URBINO   (Italy)

^g LUND UNIVERSITY   (Sweden)

Author keywords

Catalytic activity; Consensus; Drug resistance; HIV 1 integrase; Raltegravir; Subtype A

Indexed keywords

ELVITEGRAVIR; INTEGRASE; RALTEGRAVIR; 2 PYRROLIDONE DERIVATIVE; ANTIRETROVIRUS AGENT; INTEGRASE INHIBITOR; VIRUS DNA;

AFFINITY CHROMATOGRAPHY; AMINO ACID SUBSTITUTION; ARTICLE; DNA BINDING; DNA CLEAVAGE; ENZYME ACTIVE SITE; ENZYME ANALYSIS; ESCHERICHIA COLI; GENE EXPRESSION; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE A; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; ANTIVIRAL RESISTANCE; CHEMICAL MODEL; CHEMISTRY; ENZYMOLOGY; GENETICS; HIV INFECTIONS; HUMAN; MUTATION; PATHOGENICITY; THEORETICAL MODEL; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-RETROVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MODELS, CHEMICAL; MODELS, THEORETICAL; MUTATION; PYRROLIDINONES;

EID: 84901759259     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2014.02.013     Document Type: Article

References (60)

1. L. Krishnan, and A. Engelman Retroviral integrase proteins and HIV-1 DNA integration J. Biol. Chem. 287 2012 40858 40866
2. FDA approves raltegravir tablets AIDS Patient Care STDS 21 2007 889
3. FDA approves new 4-drug once-a-day HIV treatment AIDS Policy Law 27 2012 1
4. A.D. Ballantyne, and C.M. Perry Dolutegravir: first global approval Drugs 73 2013 1627 1637
5. F.J. Lee, and A. Carr Tolerability of HIV integrase inhibitors Curr. Opin. HIV AIDS 7 2012 422 428
6. J.L. Lennox The use of HIV-1 integrase inhibitors in antiretroviral naive patients Curr. Opin. HIV AIDS 7 2012 409 414
7. E. De Clercq The design of drugs for HIV and HCV Nat. Rev. Drug Discovery 6 2007 1001 1018
8. A.U. Scherrer, B. Ledergerber, V. von Wyl, J. Boni, S. Yerly, T. Klimkait, P. Burgisser, A. Rauch, B. Hirschel, M. Cavassini, L. Elzi, P.L. Vernazza, E. Bernasconi, L. Held, and H.F. Gunthard Improved virological outcome in white patients infected with HIV-1 non-B subtypes compared to subtype B Clin. Infect. Dis. 53 2011 1143 1152
9. S. Osmanov, C. Pattou, N. Walker, B. Schwardlander, and J. Esparza Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000 J. Acquired Immune Defic. Syndr. 29 2002 184 190
10. C.S. Alexander, V. Montessori, B. Wynhoven, W. Dong, K. Chan, M.V. O'Shaughnessy, T. Mo, M. Piaseczny, J.S. Montaner, and P.R. Harrigan Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia Antivir. Ther. 7 2002 31 35
11. W.P. Bannister, L. Ruiz, C. Loveday, S. Vella, K. Zilmer, J. Kjaer, B. Knysz, A.N. Phillips, and A. Mocroft HIV-1 subtypes and response to combination antiretroviral therapy in Europe Antivir. Ther. 11 2006 707 715
12. P.J. Easterbrook, M. Smith, J. Mullen, S. O'Shea, I. Chrystie, A. de Ruiter, I.D. Tatt, A.M. Geretti, and M. Zuckerman Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy J. Int. AIDS Soc. 13 2010 4
13. A.M. Geretti, L. Harrison, H. Green, C. Sabin, T. Hill, E. Fearnhill, D. Pillay, and D. Dunn Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy Clin. Infect. Dis. 48 2009 1296 1305
14. J.K. Rockstroh, H. Teppler, J. Zhao, P. Sklar, M.D. Miller, C.M. Harvey, K.M. Strohmaier, R.Y. Leavitt, and B.Y. Nguyen Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies AIDS 25 2011 1365 1369
15. C. Garrido, A.M. Geretti, N. Zahonero, C. Booth, A. Strang, V. Soriano, and C. De Mendoza Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection J. Antimicrob. Chemother. 65 2010 320 326
16. N. Sichtig, S. Sierra, R. Kaiser, M. Daumer, S. Reuter, E. Schulter, A. Altmann, G. Fatkenheuer, U. Dittmer, H. Pfister, and S. Esser Evolution of raltegravir resistance during therapy J. Antimicrob. Chemother. 64 2009 25 32
17. A.I. Maiga, I. Malet, C. Soulie, A. Derache, V. Koita, B. Amellal, L. Tchertanov, O. Delelis, L. Morand-Joubert, J.F. Mouscadet, R. Murphy, M. Cisse, C. Katlama, V. Calvez, and A.G. Marcelin Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02-AG subtypes Antivir. Ther. 14 2009 123 129
18. B.G. Brenner, M. Lowe, D. Moisi, I. Hardy, S. Gagnon, H. Charest, J.G. Baril, M.A. Wainberg, and M. Roger Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors J. Med. Virol. 83 2011 751 759
19. T. Bar-Magen, D.A. Donahue, E.I. McDonough, B.D. Kuhl, V.H. Faltenbacher, H. Xu, V. Michaud, R.D. Sloan, and M.A. Wainberg HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays AIDS 24 2010 2171 2179
20. A. Phuphuakrat, E. Pasomsub, S. Kiertiburanakul, W. Chantratita, and S. Sungkanuparph HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates AIDS Res. Hum. Retroviruses 28 2012 937 943
21. M.M. Santoro, C. Alteri, L. Ronga, P. Flandre, L. Fabeni, F. Mercurio, R. D'Arrigo, C. Gori, G. Palamara, A. Bertoli, F. Forbici, R. Salpini, E. Boumis, V. Tozzi, U. Visco-Comandini, M. Zaccarelli, M. Van Houtte, T. Pattery, P. Narciso, A. Antinori, F. Ceccherini-Silberstein, and C.F. Perno Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02-AG) in Italy AIDS Res. Hum. Retroviruses 28 2013 1285 1293
22. S.Y. Rhee, T.F. Liu, M. Kiuchi, R. Zioni, R.J. Gifford, S.P. Holmes, and R.W. Shafer Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors Retrovirology 5 2008 74
23. F. Ceccherini-Silberstein, I. Malet, L. Fabeni, S. Dimonte, V. Svicher, R. D'Arrigo, A. Artese, G. Costa, S. Bono, S. Alcaro, A. Monforte, C. Katlama, V. Calvez, A. Antinori, A.G. Marcelin, and C.F. Perno Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors J. Antimicrob. Chemother. 65 2010 2305 2318
24. M. Parczewski, D. Bander, A. Urbanska, and A. Boron-Kaczmarska HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland BMC Infect. Dis. 12 2012 368
25. K. Van Baelen, V. Van Eygen, E. Rondelez, and L.J. Stuyver Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility AIDS 22 2008 1877 1880
26. P. Isarangkura-Na-Ayuthaya, W. Kaewnoo, W. Auwanit, U.C. de Silva, K. Ikuta, P. Sawanpanyalert, and M. Kameoka Appearance of drug resistance- associated mutations in human immunodeficiency virus type 1 CRF01-AE integrase derived from drug-naive Thai patients AIDS Res. Hum. Retroviruses 26 2010 1341 1343
27. M. Monleau, A.F. Aghokeng, B.A. Nkano, M.L. Chaix, and M. Peeters Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations AIDS Res. Hum. Retroviruses 28 2012 1157 1160
28. C. Gutierrez, B. Hernandez-Novoa, M.J. Perez-Elias, A.M. Moreno, A. Holguin, F. Dronda, J.L. Casado, and S. Moreno Prevalence of primary resistance mutations to integrase inhibitors in treatment-naive and -experienced patients infected with B and non-B HIV-1 variants HIV Clin. Trials 14 2013 10 16
29. F. Ceccherini-Silberstein, K. Van Baelen, D. Armenia, M. Trignetti, E. Rondelez, L. Fabeni, F. Scopelliti, M. Pollicita, L. Van Wesenbeeck, V. Van Eygen, L. Dori, L. Sarmati, S. Aquaro, G. Palamara, M. Andreoni, L.J. Stuyver, and C.F. Perno Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors Antimicrob. Agents Chemother. 54 2010 3938 3948
30. J.L. Blanco, V. Varghese, S.Y. Rhee, J.M. Gatell, and R.W. Shafer HIV-1 integrase inhibitor resistance and its clinical implications J. Infect. Dis. 203 2011 1204 1214
31. I. Malet, O. Delelis, C. Soulie, M. Wirden, L. Tchertanov, P. Mottaz, G. Peytavin, C. Katlama, J.F. Mouscadet, V. Calvez, and A.G. Marcelin Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients J. Antimicrob. Chemother. 63 2009 795 804
32. E.Z. Loizidou, I. Kousiappa, C.D. Zeinalipour-Yazdi, D.A. Van de Vijver, and L.G. Kostrikis Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses Biochemistry 48 2009 4 6
33. J.C. Clemente, R.M. Coman, M.M. Thiaville, L.K. Janka, J.A. Jeung, S. Nukoolkarn, L. Govindasamy, M. Agbandje-McKenna, R. McKenna, W. Leelamanit, M.M. Goodenow, and B.M. Dunn Analysis of HIV-1 CRF-01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir Biochemistry 45 2006 5468 5477
34. R.M. Coman, A.H. Robbins, M.A. Fernandez, C.T. Gilliland, A.A. Sochet, M.M. Goodenow, R. McKenna, and B.M. Dunn The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease Biochemistry 47 2008 731 743
35. A.F. Bobkov, E.V. Kazennova, L.M. Selimova, T.A. Khanina, G.S. Ryabov, M.R. Bobkova, A.L. Sukhanova, A.V. Kravchenko, N.N. Ladnaya, J.N. Weber, and V.V. Pokrovsky Temporal trends in the HIV-1 epidemic in Russia: predominance of subtype A J. Med. Virol. 74 2004 191 196
36. C. Beyrer, S. Baral, A. Shaboltas, E. Dukhovlinova, A. Masharsky, S. Verevochkin, C. Latkin, R. Heimer, I. Hoffman, and A. Kozlov The feasibility of HIV vaccine efficacy trials among Russian injection drug users Vaccine 25 2007 7014 7016
37. M.M. Thomson, A. Vinogradova, E. Delgado, A. Rakhmanova, A. Yakovlev, M.T. Cuevas, M. Munoz, M. Pinilla, Y. Vega, L. Perez-Alvarez, S. Osmanov, and R. Najera Molecular epidemiology of HIV-1 in St Petersburg, Russia: predominance of subtype A, former Soviet Union variant, and identification of intrasubtype subclusters J. Acquired Immune Defic. Syndr. 51 2009 332 339
38. O.A. Rumyantseva, I.A. Olkhovskiy, M.A. Malysheva, L.A. Ruzaeva, A.V. Vasiliev, E.V. Kazennova, M.R. Bobkova, and V.V. Lukashov Epidemiological networks and drug resistance of HIV type 1 in Krasnoyarsk region, Russia AIDS Res. Hum. Retroviruses 25 2009 931 936
39. E.V. Kazennova, O.V. Antonova, S.N. Kuzin, T.P. Serkina, L.S. Sokolova, A.V. Vasil'ev, I.A. Lapovok, and M.R. Bobkova Molecular and epidemiology studies of HIV-1 prevalence in the Republic of Sakha (Yakutia) Vopr. Virusol. 56 2011 30 34
40. V. Laga, E.V. Kazennova, A.V. Vasil'ev, I.A. Lapovok, A. Ismailova, N. Beisheeva, N. Asybalieva, and M.R. Bobkova Molecular-genetic characterization of the HIV-1 variants abundant in Kirghizia Vopr. Virusol. 57 2012 26 32
41. H. Leh, P. Brodin, J. Bischerour, E. Deprez, P. Tauc, J.C. Brochon, E. LeCam, D. Coulaud, C. Auclair, and J.F. Mouscadet Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase Biochemistry 39 2000 9285 9294
42. F. Michel, C. Crucifix, F. Granger, S. Eiler, J.-F. Mouscadet, S. Korolev, J. Agapkina, R. Ziganshin, M. Gottikh, A. Nazabal, S. Emiliani, R. Benarous, D. Moras, P. Schultz, and M. Ruff Structural basis for HIV-1 DNA integration in the human genome, role of the LEDGF/P75 cofactor EMBO J. 28 2009 980 991
43. G.P. Donaldson, K.G. Roelofs, Y. Luo, H.O. Sintim, and V.T. Lee A rapid assay for affinity and kinetics of molecular interactions with nucleic acids Nucleic Acids Res. 40 2012 48
44. R.E. Myers, and D. Pillay Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase J. Virol. 82 2008 9228 9235
45. A. Low, N. Prada, M. Topper, F. Vaida, D. Castor, H. Mohri, D. Hazuda, M. Muesing, and M. Markowitz Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors Antimicrob. Agents Chemother. 53 2009 4275 4282
46. M.A. Wainberg, T. Mesplede, and P.K. Quashie The development of novel HIV integrase inhibitors and the problem of drug resistance Curr. Opin. Virol. 2 2012 656 662
47. G.S. Jones, F. Yu, A. Zeynalzadegan, J. Hesselgesser, X. Chen, J. Chen, H. Jin, C.U. Kim, M. Wright, R. Geleziunas, and M. Tsiang Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase Antimicrob. Agents Chemother. 53 2009 1194 1203
48. M. Kobayashi, K. Nakahara, T. Seki, S. Miki, S. Kawauchi, A. Suyama, C. Wakasa-Morimoto, M. Kodama, T. Endoh, E. Oosugi, Y. Matsushita, H. Murai, T. Fujishita, T. Yoshinaga, E. Garvey, S. Foster, M. Underwood, B. Johns, A. Sato, and T. Fujiwara Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants Antiviral Res. 80 2008 213 222
49. E.C. Reuman, M.H. Bachmann, V. Varghese, W.J. Fessel, and R.W. Shafer Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector Antimicrob. Agents Chemother. 54 2010 934 936
50. O. Delelis, K. Carayon, E. Guiot, H. Leh, P. Tauc, J.C. Brochon, J.F. Mouscadet, and E. Deprez Insight into the integrase-DNA recognition mechanism. A specific DNA-binding mode revealed by an enzymatically labeled integrase J. Biol. Chem. 283 2008 27838 27849
51. R. Craigie, and F.D. Bushman HIV DNA integration Cold Spring Harb. Perspect. Med. 2 2012 a006890
52. M. Smolov, M. Gottikh, V. Tashlitskii, S. Korolev, I. Demidyuk, J.C. Brochon, J.-F. Mouscadet, and E. Deprez Kinetic study of the HIV-1 DNA 3′-end processing FEBS J. 273 2006 1137 1151
53. O. Delelis, I. Malet, L. Na, L. Tchertanov, V. Calvez, A.G. Marcelin, F. Subra, E. Deprez, and J.F. Mouscadet The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation Nucleic Acids Res. 37 2009 1193 1201
54. O. Delelis, V. Parissi, H. Leh, G. Mbemba, C. Petit, P. Sonigo, E. Deprez, and J.-F. Mouscadet Efficient and specific internal cleavage of a retroviral palindromic DNA sequence by tetrameric HIV-1 integrase PLoS ONE 2 2007 e608
55. I. Malet, O. Delelis, M.A. Valantin, B. Montes, C. Soulie, M. Wirden, L. Tchertanov, G. Peytavin, J. Reynes, J.-F. Mouscadet, C. Katlama, V. Calvez, and A.G. Marcelin Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro Antimicrob. Agents Chemother. 52 2008 1351 1358
56. M. Métifiot, K. Maddali, A. Naumova, X. Zhang, C. Marchand, and Y. Pommier Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir Biochemistry 49 2010 3715 3722
57. S. Sinha, and D.P. Grandgenett Recombinant human immunodeficiency virus type 1 integrase exhibits a capacity for full-site integration in vitro that is comparable to that of purified preintegration complexes from virus-infected cells J. Virol. 79 2005 8208 8216
58. S. Hare, M.C. Shun, S.S. Gupta, E. Valkov, A. Engelman, and P. Cherepanov A novel co-crystal structure affords the design of gain-of-function lentiviral integrase mutants in the presence of modified PSIP1/LEDGF/p75 PLoS Pathog. 5 2009 e1000259
59. V. Summa, A. Petrocchi, F. Bonelli, B. Crescenzi, M. Donghi, M. Ferrara, F. Fiore, C. Gardelli, O. Gonzalez Paz, D.J. Hazuda, P. Jones, O. Kinzel, R. Laufer, E. Monteagudo, E. Muraglia, E. Nizi, F. Orvieto, P. Pace, G. Pescatore, R. Scarpelli, K. Stillmock, M.V. Witmer, and M. Rowley Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection J. Med. Chem. 51 2008 5843 5855
60. K. Shimura, E. Kodama, Y. Sakagami, Y. Matsuzaki, W. Watanabe, K. Yamataka, Y. Watanabe, Y. Ohata, S. Doi, M. Sato, M. Kano, S. Ikeda, and M. Matsuoka Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137) J. Virol. 82 2008 764 774